BIAXIN (Clarithromycin) warning

A study showing a higher death rate among heart disease patients one year after taking the Abbott Laboratories Inc. antibiotic Biaxin recently published in the British Medical Journal, evaluated data from about 4,373 Danish heart disease patients who took Biaxin (clarithromycin) or a placebo for 14 days. Researchers said 9.8 percent of Biaxin patients died within three years of treatment, compared with 7.8 percent of people who got a placebo. There were no differences in the death rates until a year following therapy.